Navigation Links
Vermillion Announces CEO Succession Plan
Date:5/15/2012

AUSTIN, Texas, May 15, 2012 /PRNewswire/ -- The board of directors of Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has begun the process of identifying a successor to Gail S. Page, president and CEO. The board has formed a search committee, with the goal of completing the search by September 2012.

James S. Burns, Vermillion's chairman of the board, commented: "During her tenure, Gail led the divestiture of the company's original research tools business, obtained FDA approval for OVA1® (the first proteomic IVDMIA to be cleared by the FDA), launched and commercialized OVA1 with Quest Diagnostics, created a molecular diagnostic development pipeline, and most recently, resolved major long-standing pieces of litigation with favorable outcomes for the company."

"Vermillion now enters a new commercial phase," continued Burns, "one in which we can expand the market for OVA1, continue OVA2™ and PAD development, and seek additional opportunities for Vermillion to build a molecular diagnostic franchise both on its own and in partnership with other companies. A leadership change at this point is consistent with our plans to advance the company to its next phase of growth. On behalf of the entire board, I would like to thank Gail for her dedication and outstanding service to Vermillion. Her achievements have been key to both the survival and early growth of our company. We wish her the very best in her new endeavors and look forward to a smooth transition."

Page commented: "I would like to thank the board, our shareholders and my colleagues who provided the opportunity to lead Vermillion during my tenure. The company has succeeded in a true pioneering effort, thanks to the hard work of its management and employees. I would especially like to thank those who worked tirelessly to help make OVA1 a life-saving test for the women who
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
3. Vermillion Completes the Acquisition of Correlogic Systems Ovarian Cancer Diagnostics Business
4. Vermillion Reports Results for Third Quarter 2011
5. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
6. Vermillion Engages Liolios Group to Lead Investor Relations Program
7. Vermillion Enhances Management Team With A Key Addition
8. Vermillion Appoints Distribution Partner for OVA1® in Israel and the Palestine Territories
9. Vermillion Reports Financial Results for the First Quarter 2011
10. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
11. Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... neutrality during wakefulness and is restored during sleep, suggests ... 9, 2010, in San Antonio, Texas, at SLEEP 2010, ... Societies LLC. Results indicate that prior wakefulness caused ... slightly but significantly greenish tint. Overnight sleep restored ...
... satisfaction is related to the amount of sleep they ... research abstract that will be presented Wednesday, June 9, ... 24th annual meeting of the Associated Professional Sleep Societies ... new parents was strongly associated with objective total sleep ...
... rate of disease progression in a clinical trial of ... Hopkins, Roswell Park Cancer Institute and Duke University. ... blood supply to prostate tumors by blocking new blood ... blood vessels to supply nutrients. The multicenter trial ...
... Stress-reducing psychological intervention helps to increase survival and ... cancer over the long-term, according to results of ... Cancer Research , a journal of the American ... intervention arm evidenced significant emotional improvement and more ...
... quality of human life ― especially embryonic stem cells, which ... However, basic scientific problems still remain unresolved but Tel ... "In order to use embryonic stem cells as ... strategies to control their differentiation so we get exactly the ...
... Drug Administration,s abilities to discover potential threats to food ... by impediments to efficient use of its limited resources ... on risks, says a new report by the Institute ... more proactively tackle food safety problems, FDA should implement ...
Cached Medicine News:Health News:Sleep colors your view of the world: Study suggests sleep may restore color perception 2Health News:First-time parents' daily sleep duration predicts their relationship satisfaction 2Health News:Drug that restricts blood supply to prostate tumors delays disease progression 2Health News:Psychological intervention provides enduring health benefits for women with breast cancer 2Health News:A launchpad for stem cell research 2Health News:FDA should adopt risk-based approach to food safety 2Health News:FDA should adopt risk-based approach to food safety 3
... Soft white rubber tube with Murphy eye. ... tube. Two high volume cuffs (One inside other) ... is designed to allow maximum access and optimum ... ventilation. The tube shaft has a special laser-guard ...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. St...
... For Rapid Medication Delivery., ,Designed ... cuffed tube incorporates an additional lumen ... delivery below the cuff., ,SHERIDAN ... allow for CO2 monitoring, pressure monitoring ...
Medicine Products: